Life Sciences

  • November 06, 2026

    'Halfhearted' Conferral Not Enough In Mosquito-Patch Feud

    A Florida federal judge on Thursday denied a bid by a German mosquito-bite patch maker to compel arbitration of a dispute over a license and distribution agreement for the products, ruling that the company's "halfhearted" conferral attempt with opposing counsel violated local rules.

  • November 06, 2026

    $45M Deal In IRhythm Heart Device Investor Suit Gets Final OK

    A California federal court granted final approval to a $45 million settlement resolving proposed class action allegations that digital healthcare company iRhythm Technologies inflated stock prices with misrepresentations about its heart-event monitoring device.

  • November 06, 2026

    GSK, Moderna End COVID Vaccine Patent Fight In Delaware

    GlaxoSmithKline and Moderna dismissed two Delaware federal patent suits Friday over Moderna's COVID-19 and respiratory syncytial virus vaccines, following a broader settlement in which the companies agreed to license patents to each other.

  • November 06, 2026

    Glenmark's $30M Drug Price-Fixing Deal Gets Final OK

    A Connecticut federal judge has granted final approval to a $29.6 million settlement between dozens of states and Glenmark Pharmaceuticals that resolves claims accusing the company of conspiring with competitors to drive up drug prices.

  • November 06, 2026

    J&J Hit With $1.9M Verdict Over Talc User's Cancer

    A Massachusetts jury said Friday that Johnson & Johnson owes $1.9 million for causing the mesothelioma, but not the death, of a former talcum powder user who also had a heart condition.

  • November 06, 2026

    Medtronic Hit With Antitrust Suit Over Surgical Stapler

    Medical device giant Medtronic Inc. is unlawfully monopolizing the market for a type of medical stapler by blocking competitive product trials and using exclusionary bundling tactics in its deals with hospital customers, according to a rival's complaint in Massachusetts federal court.

  • November 06, 2026

    IP Atty Reaches Deal To End FCA Suit Over Apriso Patent

    An intellectual property attorney has entered a settlement to resolve his False Claims Act suit against the pharmaceutical company Bausch alleging it fraudulently obtained a patent to block the production of a generic ulcerative colitis medication, Apriso.

  • November 06, 2026

    Taxation With Representation: Wilson Sonsini, Fenwick

    In this week's Taxation With Representation, Marvell Technology buys data center optics maker Lumentum, defense technology company Shield acquires radar company Echodyne, and CVS Health plans to split into two independent, publicly traded companies.

  • November 05, 2026

    J&J Should Pay $60M For Talc User's Cancer, Jury Told

    Johnson & Johnson should pay $60 million for the death of a woman who developed mesothelioma alongside her heart problems after using talc products allegedly contaminated with asbestos, counsel for her family told a Massachusetts state jury during closing arguments Thursday.

  • November 05, 2026

    In Moderna Row, Fed. Circ. Mulls What's 'For The Government'

    The Federal Circuit on Thursday took a critical look at a lower court's decision concluding that Moderna had to face Arbutus' infringement claims over its COVID-19 vaccines, with one judge repeatedly asking why Moderna's vaccine efforts weren't "for the government" within the meaning of a statutory shield for contractors.

  • November 05, 2026

    5 Firms Guide Brains Bioceutical's $750M SPAC Merger

    Cannabinoid life sciences and pharmaceutical company Brains Bioceutical Corp. on Thursday unveiled plans to go public by merging with special purpose acquisition company Armada Acquisition Corp. III in a deal that values it at roughly $750 million and that was built by five law firms.

  • November 05, 2026

    Invitae Privacy Suit Must Get OK From NJ Bankruptcy Judge

    A New Jersey bankruptcy judge said Thursday he will need to see more evidence to resolve an "ambiguity" over whether class action privacy claims against genetic testing company Invitae Corp. belong in his court.

  • November 05, 2026

    Ex-Sales Leader Violated 'Secrecy' Pact, J&J Ortho Unit Says

    Johnson & Johnson's orthopedic device unit DePuy Synthes alleged in New Jersey federal court that a former national sales leader's move to a rival violates several of his employment agreements, asking the court to order expedited discovery and block him from contacting any of its customers.

  • November 05, 2026

    Albertsons, Safeway Owe Wash. $900M Over Opioid Diversion

    Albertsons and its Safeway subsidiary must pay $900 million for helping fuel Washington state's overdose crisis by failing for years to prevent the diversion of opioid drugs, a Seattle judge ruled Thursday, finding that the pharmacy chains regularly failed to follow their own policies aimed at ensuring prescriptions were legitimate.

  • November 05, 2026

    Ropes & Gray-Led Pharma Biz Offers $541M For Swedish Rival

    U.S. biopharma company ANI said Thursday it has offered to acquire Swedish pharmaceutical company Egetis for up to approximately 5.3 billion Swedish kronor ($541 million) to gain access to a newly approved drug.

  • November 04, 2026

    Pharmacy Worker Says Dosage Machine Cut Off Fingertip

    A pharmacy worker suffered a "traumatic" finger amputation when a machine that dispenses liquid medication caught her index finger and ripped part of it off, according to a lawsuit in Pennsylvania state court that accuses medical device manufacturer Precision Products Group Inc. of defective design.

  • November 04, 2026

    Anti-Pot Group Eyes New Repeal Pushes After Mass. Loss

    After Election Day, anti-cannabis activists are pledging to bring repeal efforts to other states despite a decisive defeat in Massachusetts, while pro-cannabis industry and consumer-focused groups say they hope to work with a Democrat-controlled Congress to secure federal reform.

  • November 04, 2026

    2nd Circ. Told To Not Expand Antitrust Patent Fraud Standing

    A pharmaceutical industry trade group has backed Bristol-Myers Squibb and its Celgene subsidiary in the Second Circuit, warning that health plans asking the appeals court to reinstate a proposed class action against the companies are seeking to expand who can bring antitrust cases alleging fraudulently obtained patents.

  • November 04, 2026

    Gene Firm Sues Pentagon Over 'Chinese Military' Label

    A Chinese genetic sequencing company has sued the Pentagon, saying it was wrongly labeled a "Chinese military company" without a warning or a chance to respond.

  • November 04, 2026

    AGs Say Taro's $200M MDL Deal Doesn't Bar Their Claims

    Dozens of state attorneys general urged a Connecticut federal judge Tuesday not to let Taro Pharmaceuticals block a swath of their price-fixing claims with a $200 million settlement it struck with plaintiffs in separate multidistrict litigation, arguing the claims and plaintiffs are too separate to bind one another.

  • November 04, 2026

    Walgreens Seeks Sanctions In Investors' Pharma Growth Suit

    Walgreens has asked an Illinois federal judge to sanction investors and their attorneys in a securities fraud class action, arguing they continued to falsely attribute statements about the company's plans to open hundreds of clinics to a former executive even after a recording showed his statement was taken out of context.

  • November 04, 2026

    CVS To Split In 2, Unraveling Decade-Old Megamerger

    CVS Health said Wednesday that it plans to split into two independent, publicly traded companies, separating its Aetna- and Caremark-led healthcare businesses from its 9,000 retail pharmacy locations, reversing its nearly decade-old combination of the businesses.

  • November 03, 2026

    Va., Mo. Voters Deliver Wins For Abortion Rights

    Supporters of abortion access won key victories Tuesday in Virginia and Missouri as voters across the country took up healthcare measures that will shape state laws on reproductive and gender-affirming care, according to partial, unofficial returns.

  • November 03, 2026

    Feds Dropping Charges Against Harvard Researcher

    The government is dropping charges against a Harvard researcher and Russian national who was found with preserved clawed frog embryo samples at Boston's Logan International Airport last year, according to a filing Tuesday evening.

  • November 03, 2026

    Birth Control Clip Maker Must Face Injury Case Trial

    Medical device importer and distributor CooperSurgical Inc. failed to secure quick wins on several claims in a bellwether product liability case alleging injuries from Filshie Clip birth control devices, with a Connecticut state judge finding that federal law does not preempt six women's failure-to-warn allegations.

Expert Analysis

  • 2 Del. Rulings Show Postclosing Earnout Arrangement Risks

    Author Photo

    Two recent Delaware Court of Chancery decisions illustrate the contractual and fiduciary duty risks associated with earnout provisions in M&A transactions, offering lessons on allocating postclosing control, drafting enforceable earnout covenants and managing executives whose pay depends on the outcome, says Chris Brown at Taft.

  • Opinion

    Judges Must Turn To Merits Earlier To Fix Civil Justice System

    Author Photo

    The U.S. justice system is long overdue for a cultural shift that encourages judges to engage with the merits of a case from the outset, which would help to cut through procedural complexities and deliver high-quality justice efficiently and at lower cost, says Steven Kayman at Rottenberg Lipman.

  • How Analytical Advances Reshape Biologic Patent Strategy

    Author Photo

    As regulators shift away from relying on comparative clinical efficacy studies in biosimilar development, and more toward analytical data, practitioners should pay closer attention to post-translational modifications when evaluating patentability, says Gina Nellesen at Global Patent Group.

  • Series

    Open-Water Swimming Makes Me A Better Lawyer

    Author Photo

    Swimming long distances in open waters is not necessarily an escape from my intellectual property practice, but a complementary discipline that similarly rewards sustained attention, intellectual curiosity, resilience and the ability to pursue a distant objective without losing command of the immediate task, says Christina MacDougall at Morgan Lewis.

  • Opinion

    The Invisible AI Danger That May Undermine Legal Profession

    Author Photo

    A public database tracking cases involving hallucinations generated by artificial intelligence recently surpassed 2,200 entries, but the bigger risk underlying attorneys’ use of such tools is that they will slowly surrender their judgment to AI and lose analytical skills, says Massachusetts District Court Associate Justice Brian Palmucci.

  • How Cos. Using AI Agents Can Avoid Protected Data Incidents

    Author Photo

    For businesses whose deployed artificial intelligence agents could enter other companies' systems and steal protected data, deployers can take several steps before an incident to test the configured agent, such as limiting it to approved systems and destinations and requiring human escalation when tasks stall, says Steven Carlson at von Briesen & Roper.

  • FDA Classification Setback Bodes Well For Wound Care Cos.

    Author Photo

    A Georgia federal court's recent decision in MiMedx v. U.S. Food and Drug Administration constrains the FDA's analytical framework for classifying certain wound care products as biological products, carrying important ramifications for manufacturers seeking to avoid heightened regulatory requirements, say attorneys at Hyman Phelps.

  • Lessons For Cannabis Dispensaries From Web Tracking Suits

    Author Photo

    The trajectory of health-tracking litigation in Florida and elsewhere suggests that patient privacy claims will not disappear quickly, so dispensaries should audit their sites, tighten consent and align their disclosures with their actual practices, say attorneys at Buchanan Ingersoll.

  • How AI Could Help Judges Spot Their Own Biases

    Author Photo

    In close cases where there’s room for discretion, artificial intelligence could challenge judges’ implicit biases by running counterfactual tests at scale — but any judicial use of such tools would need guardrails, say Arnold Peter at Peter Law and Nancy Rapoport at University of Nevada.

  • 3 Eligibility Rulings Show Risks Of Broad Claim Constructions

    Author Photo

    Several recent decisions from the Federal Circuit, including its ruling in Berkeley v. W.W. Grainger, highlight the importance of identifying the inventive aspects of a patent early in the case so that patentees do not inadvertently read the inventive features out of their own claims, say attorneys at MoFo.

  • 3 Strategies To Reduce AI Sycophancy In Legal Work

    Author Photo

    The tendency of generative artificial intelligence models to tell users what they want to hear can reinforce attorneys’ confirmation bias when testing the strength of arguments, and it can’t simply be prompted away — but a few practices can help mitigate it, says Michael Ott at Ice Miller.

  • DOJ Directive Gives Contractors A Fraud Risk Road Map

    Author Photo

    For government contractors, the 10 factors described in the U.S. Department of Justice's recent corporate fraud enforcement directive function as a de facto scoring rubric for internal audits that mirrors what prosecutors will prioritize, say attorneys at Spencer Fane.

  • Why Inter Partes Reviews May Be On The Rebound

    Author Photo

    Recent inter partes review data shows that rates of referrals and institution rates at the U.S. Patent and Trademark Office are increasing, potentially indicating, among other reasons, that patent challengers are adjusting to the USPTO's policy changes, say attorneys at Sterne Kessler.

  • 2nd Circ. EFAA Ruling Shifts Employer Litigation Strategy

    Author Photo

    In Diaz-Roa v. Hermes Law, the Second Circuit recently held that, under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act, employers can't carve out nonharassment claims and send them to arbitration, which has implications for discovery, litigation costs and resolution strategy in EFAA-covered disputes, say attorneys at Krevolin Horst.

  • 3rd Circ. Ruling Opens Door For Fraud-On-The-Market Rethink

    Author Photo

    The Third Circuit's recent decision in Ocugen, holding that a stable stock price after publication of restated financials does not prove immateriality, could be a vehicle for the U.S. Supreme Court to overturn the doctrine undergirding certification of securities class actions, says Jonathan Richman at Brown Rudnick.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here